Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fulcrum Therapeutics (FULC) EBT Margin (2020 - 2024)

Historic EBT Margin for Fulcrum Therapeutics (FULC) over the last 5 years, with Q2 2024 value amounting to 69.26%.

  • Fulcrum Therapeutics' EBT Margin rose 27718700.0% to 69.26% in Q2 2024 from the same period last year, while for Dec 2024 it was 12.16%, marking a year-over-year increase of 34579000.0%. This contributed to the annual value of 12.16% for FY2024, which is 34579000.0% up from last year.
  • As of Q2 2024, Fulcrum Therapeutics' EBT Margin stood at 69.26%, which was up 27718700.0% from 2842.25% recorded in Q4 2023.
  • Fulcrum Therapeutics' EBT Margin's 5-year high stood at 69.26% during Q2 2024, with a 5-year trough of 8399.66% in Q1 2023.
  • For the 5-year period, Fulcrum Therapeutics' EBT Margin averaged around 1885.27%, with its median value being 1026.08% (2020).
  • Per our database at Business Quant, Fulcrum Therapeutics' EBT Margin plummeted by -73993500bps in 2023 and then soared by 27718700bps in 2024.
  • Quarter analysis of 5 years shows Fulcrum Therapeutics' EBT Margin stood at 419.41% in 2020, then decreased by -11bps to 464.29% in 2021, then plummeted by -722bps to 3815.33% in 2022, then rose by 26bps to 2842.25% in 2023, then skyrocketed by 102bps to 69.26% in 2024.
  • Its EBT Margin was 69.26% in Q2 2024, compared to 2842.25% in Q4 2023 and 3164.3% in Q3 2023.